StockData
Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc. (OTLC) stock

OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.02+0.00 (+11.45%)

Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –

Oncotelic Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Oncotelic Therapeutics's total assets was $394.75M at Jun 30, 2026. For fiscal 2025 it was $393.09M, up 1373.5% from the year before. Over ten years it grew 30.5% a year on average. The highest annual figure on record is $393.09M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$393.09M+1373.5%
FY2024Dec 31, 2024$26.68M-11.1%
FY2023Dec 31, 2023$30.01M-16.9%
FY2022Dec 31, 2022$36.12M+53.0%
FY2021Dec 31, 2021$23.61M-0.2%
FY2020Dec 31, 2020$23.66M-0.1%
FY2019Dec 31, 2019$23.68M+762.0%
FY2018Dec 31, 2018$2.75M+134.5%
FY2017Dec 31, 2017$1.17M-91.7%
FY2016Dec 31, 2016$14.11M-48.6%
FY2015Dec 31, 2015$27.45M-9.8%
FY2014Dec 31, 2014$30.42M+317.1%
FY2013Dec 31, 2013$7.29M+33.9%
FY2012Dec 31, 2012$5.45M-50.7%
FY2011Dec 31, 2011$11.06M+98.6%
FY2010Dec 31, 2010$5.57M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$394.75M+1380.2%
Q1 FY2026Mar 31, 2026$393.96M+1376.7%
Q4 FY2025Dec 31, 2025$393.09M+1367.7%
Q2 FY2025Jun 30, 2025$26.68M-10.9%
Q1 FY2025Mar 31, 2025$26.67M-11.0%
Q4 FY2024Dec 31, 2024$26.68M-11.1%
Q3 FY2024Sep 30, 2024$26.78M-11.0%
Q2 FY2024Jun 30, 2024$29.94M-0.3%
Q1 FY2024Mar 31, 2024$29.97M-16.8%
Q4 FY2023Dec 31, 2023$30.01M-16.9%
Q3 FY2023Sep 30, 2023$30.10M-25.2%
Q2 FY2023Jun 30, 2023$30.01M-25.7%
Q1 FY2023Mar 31, 2023$36.05M+55.8%
Q4 FY2022Dec 31, 2022$36.12M+53.0%
Q3 FY2022Sep 30, 2022$40.24M+73.5%
Q2 FY2022Jun 30, 2022$40.39M+70.3%
Q1 FY2022Mar 31, 2022$23.13M-3.6%
Q4 FY2021Dec 31, 2021$23.61M-0.2%
Q3 FY2021Sep 30, 2021$23.19M-5.8%
Q2 FY2021Jun 30, 2021$23.71M-1.3%
Q1 FY2021Mar 31, 2021$23.99M+1.7%
Q4 FY2020Dec 31, 2020$23.66M-0.1%
Q3 FY2020Sep 30, 2020$24.63M+227.1%
Q2 FY2020Jun 30, 2020$24.01M+213.5%
Q1 FY2020Mar 31, 2020$23.60M+5934.9%
Q4 FY2019Dec 31, 2019$23.68M+762.0%
Q3 FY2019Sep 30, 2019$7.53M+555.2%
Q2 FY2019Jun 30, 2019$7.66M+264.9%
Q1 FY2019Mar 31, 2019$391.00K-10.5%
Q4 FY2018Dec 31, 2018$2.75M+134.5%
Q3 FY2018Sep 30, 2018$1.15M-61.4%
Q2 FY2018Jun 30, 2018$2.10M-67.9%
Q1 FY2018Mar 31, 2018$437.00K-95.7%
Q4 FY2017Dec 31, 2017$1.17M-91.7%
Q3 FY2017Sep 30, 2017$2.98M-82.8%
Q2 FY2017Jun 30, 2017$6.53M-68.0%
Q1 FY2017Mar 31, 2017$10.18M–
Q4 FY2016Dec 31, 2016$14.11M–
Q3 FY2016Sep 30, 2016$17.26M–
Q2 FY2016Jun 30, 2016$20.43M–

More Oncotelic Therapeutics figures

See a number that looks wrong?